Tumors with high mutational loads, in the range of 5–10 somatic mutations per megabase of DNA, such as NSCLC [89] and SCLC [92,93], are highly immunogenic and correlate with a high ORR, extended PFS and/or durable benefit after PD-1 blocker treatment. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.